© 2017 • Sabin Vaccine Institute • 2175 K Street, NW, Suite 400 • Washington, DC 20037 • +1 202 842 5025
Sabin has led a number of studies to better determine the burden of pneumococcal disease and the impact of vaccination.
Pneumococcal Disease Burden in the Over-Five Years Old Age Groups
In partnership with the International Vaccine Access Center at Johns Hopkins University (IVAC), the Pan American Health Organization (PAHO) and the U.S. Centers for Disease Control and Prevention (CDC), Sabin is working to collect and review country-level data from Argentina, Brazil, Chile, Colombia and Uruguay on the burden of invasive and non-invasive pneumococcal disease by age group in Latin America and the Caribbean, focusing on those five years and older. The study also aims to describe the cost of illness of pneumococcal disease, the trends of serotype distribution and analyze awareness of the epidemiology of pneumococcal disease for these groups.
Burden of Pediatric Pneumococcal Disease in Latin America and the Caribbean
Sabin also conducted a comprehensive study to estimate the burden of pediatric pneumococcal disease in the Latin America and Caribbean region, as well as the cost effectiveness of pneumococcal vaccination in children. The report found that more than 18,000 children die every year in the region from pneumococcal disease, and revealed that the region was spending more than U.S. $294 million in direct medical costs to treat these diseases.
PCV Effectiveness on Hospitalizations and Deaths from Childhood Pneumococcal Disease
In Chile, Colombia and Peru work is being conducted by Sabin, in partnership with the Pan American Health Organization (PAHO), to assess the impact and effectiveness of pneumococcal conjugate vaccine (PCV) on hospitalizations and deaths due to childhood pneumonia, following PCV’s introduction into the national immunization programs of these countries. Studies demonstrating the effect of PCV vaccination on pneumococcal morbidity and mortality in middle income countries with high disease burden are scarce. Showing the impact of the vaccine, through its routine use in the national immunization program, will provide the best information on the potential benefit of pneumococcal conjugate mass vaccination in order to help guide national health policies in other countries.